Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst , Paul Baas , Dong‐Wan Kim +16 more 2015 The Lancet 6378 citations
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update María Reig , Alejandro Forner , Jordi Rimola +13 more 2021 Journal of Hepatology 3634 citations